Építés alatt – nem éles oldal

Ugrás a tartalomra

Frontlight Research

Vizsgálati helyszín

Asklepios Klinik Altona

Hamburg, Hamburg (Hansestadt) 22763, NémetországMég nincs intézményhez kötve

26futó vizsgálat
16lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 43 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Vastagbélrák8 vizsgálat
Pitvarfibrilláció7 vizsgálat
Hasnyálmirigyrák5 vizsgálat
Mielóma multiplex5 vizsgálat
Tüdőrák5 vizsgálat
Akut mieloid leukémia (AML)4 vizsgálat
Gyomor- és nyelőcsőrák4 vizsgálat
Stroke (szélütés)4 vizsgálat
Fej-nyaki daganatok3 vizsgálat
Gyermekkori daganatok2 vizsgálat
Máj- és epeúti rák2 vizsgálat
Méhtestrák2 vizsgálat
és még 11
Fázis: 3. fázis14 vizsgálat
2. fázis9 vizsgálat
1/2. fázis3 vizsgálat
1. fázis1 vizsgálat
Állapot: Lezárult16 vizsgálat
Toboroz16 vizsgálat
Fut, nem toboroz9 vizsgálat
Még nem toboroz1 vizsgálat
Felfüggesztve1 vizsgálat
Fő szponzor: Janssen Research & Development, LLC4 vizsgálat
CVRx, Inc.3 vizsgálat
Ipsen3 vizsgálat
University of Ulm3 vizsgálat
Asklepios proresearch2 vizsgálat
és még 25

Futó vizsgálatok

Még nem toboroz
Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care
NCT07699640· Heinrich-Heine University, Duesseldorf· Forrás
Contact: Christian Wülfing
Toboroz
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
NCT07176312· 2. fázis· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Forrás
Contact: Dirk Arnold, Prof. Dr.
Fut, nem toboroz
WATCHMAN FLX Pro European Registry
NCT07262255· Boston Scientific Corporation· Forrás
Toboroz
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
NCT06607458· 2. fázis· Delcath Systems Inc.· Forrás
Contact: Matthew Cooney, MD
Toboroz
VASC-AF Study: Vascular Closure vs Manual Compression
NCT07414121· Asklepios proresearch· Forrás
Contact: Christian-Hendrik Heeger, Prof. Dr.
Toboroz
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
COCONUT Study Concomitant PVI and LAAC
NCT06861673· Asklepios proresearch· Forrás
Contact: Christian-Hendrik Heeger, Prof. Dr.
Toboroz
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
NCT05976685· Insel Gruppe AG, University Hospital Bern· Forrás
Contact: Joachim Röther
Fut, nem toboroz
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475· 3. fázis· TransThera Sciences (Nanjing), Inc.· Forrás
Toboroz
Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI
NCT05786131· Leipzig Heart Science gGmbH· Forrás
Contact: Felix Meincke, MD
Fut, nem toboroz
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study of Daratumumab
NCT05438043· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
NCT04628026· 3. fázis· University of Ulm· Forrás
Toboroz
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444· Guardant Health, Inc.· Forrás
Contact: Petra Frey
Toboroz
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750· 1/2. fázis· PMV Pharmaceuticals, Inc· Forrás
Contact: Dirk Arnold, MD
Toboroz
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
NCT04298723· Jena University Hospital· Forrás
Contact: Felix Meincke, Dr.
Fut, nem toboroz
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
NCT04230759· 2. fázis· Goethe University· Forrás
Fut, nem toboroz
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Additional Left Atrial Appendage Isolation During Balloon Ablation for Persistent or Long-standing Persistent Atrial Fibrillation
NCT04240366· University of Luebeck· Forrás
Contact: Christian H. Heeger, Prof. Dr.
Fut, nem toboroz
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
NCT03897127· 3. fázis· University of Ulm· Forrás
Fut, nem toboroz
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
NCT03647878· Ipsen· Forrás
Toboroz
BAROSTIM THERAPY™ In Resistant Hypertension
NCT02880631· CVRx, Inc.· Forrás
Contact: Christine Neumann
Toboroz
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction
NCT02880618· CVRx, Inc.· Forrás
Contact: Nicole Baumann
Fut, nem toboroz
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949· 2. fázis· Partner Therapeutics, Inc.· Forrás
Toboroz
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
NCT01252485· University of Ulm· Forrás
Contact: Hans Salwender, Dr.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Lezárult
Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions
NCT05499832· 3. fázis· Insel Gruppe AG, University Hospital Bern· Forrás
Fut, nem toboroz
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05287113· 2. fázis· Incyte Biosciences International Sàrl· Forrás
Lezárult
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
NCT05383352· 1. fázis· Ipsen· Forrás
Lezárult
Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
NCT04813627· BioNTech SE· Forrás
Fut, nem toboroz
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378· 2. fázis· BioNTech SE· Forrás
Lezárult
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
NCT04472429· 3. fázis· Incyte Corporation· Forrás
Lezárult
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
NCT04191616· 2. fázis· Amgen· Forrás
Lezárult
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
NCT04495621· 1/2. fázis· Menarini Group· Forrás
Lezárult
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235· 3. fázis· Ipsen· Forrás
Lezárult
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
NCT04221529· 2. fázis· AIO-Studien-gGmbH· Forrás
Fut, nem toboroz
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030· 3. fázis· Bristol-Myers Squibb· Forrás
Lezárult
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
NCT03615326· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03412565· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
NCT03267316· 1/2. fázis· Cantargia AB· Forrás
Lezárult
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
NCT02876042· CVRx, Inc.· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 15.

Építés alatt, nem éles – Asklepios Klinik Altona: vizsgálati helyszín – Frontlight Research